-
1
-
-
23044510136
-
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
-
Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4079-4088
-
-
Keating, M.J.1
O'Brien, S.2
Albitar, M.3
-
2
-
-
19944429446
-
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparison analysis of CALGB9712 and CALGB9011
-
Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparison analysis of CALGB9712 and CALGB9011. Blood. 2005;105:49-53.
-
(2005)
Blood
, vol.105
, pp. 49-53
-
-
Byrd, J.C.1
Rai, K.2
Peterson, B.L.3
-
3
-
-
0037106502
-
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
-
Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891-3897.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3891-3897
-
-
Rai, K.R.1
Freter, C.E.2
Mercier, R.J.3
-
4
-
-
21144456107
-
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
-
Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2971-2979
-
-
Moreton, P.1
Kennedy, B.2
Lucas, G.3
-
5
-
-
0031757274
-
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
-
Ludin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. J Clin Oncol. 1998;16:3257-3263.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3257-3263
-
-
Ludin, J.1
Osterborg, A.2
Brittinger, G.3
-
6
-
-
0344236261
-
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
-
O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98:2657-2663.
-
(2003)
Cancer
, vol.98
, pp. 2657-2663
-
-
O'Brien, S.M.1
Kantarjian, H.M.2
Thomas, D.A.3
-
7
-
-
1942442044
-
Alemtuzumab for minimal residual disease in CLL
-
Abstract 371
-
O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab for minimal residual disease in CLL. Blood. 2003;102:109a. Abstract 371.
-
(2003)
Blood
, vol.102
-
-
O'Brien, S.M.1
Kantarjian, H.M.2
Thomas, D.A.3
-
8
-
-
14944343819
-
Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network
-
Hainsworth JD, Litchy S, Morrissey LH, et al. Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1500-1506.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1500-1506
-
-
Hainsworth, J.D.1
Litchy, S.2
Morrissey, L.H.3
-
9
-
-
0029981025
-
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
-
Cheson BD, Bennett JA, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
-
(1996)
Blood
, vol.87
, pp. 4990-4997
-
-
Cheson, B.D.1
Bennett, J.A.2
Grever, M.3
-
10
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma
-
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244-1255.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1244-1255
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
-
11
-
-
33845382806
-
Non-parametric estimation from incomplete observations
-
Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
-
(1958)
J Am Stat Assoc
, vol.53
, pp. 457-481
-
-
Kaplan, E.L.1
Meier, P.2
-
12
-
-
33751009390
-
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia
-
Fiegl M, Falkner A, Hopfinger G, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia. Cancer. 2006;107:2408-2416.
-
(2006)
Cancer
, vol.107
, pp. 2408-2416
-
-
Fiegl, M.1
Falkner, A.2
Hopfinger, G.3
-
13
-
-
33744793781
-
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia
-
Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 2006;24:2337-2342.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2337-2342
-
-
Montillo, M.1
Tedeschi, A.2
Miqueleiz, S.3
-
14
-
-
38049002872
-
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
-
Abstract 33
-
Schweighofer C, Ritgen M, Eichhorst B, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Blood. 2006;108:14a. Abstract 33.
-
(2006)
Blood
, vol.108
-
-
Schweighofer, C.1
Ritgen, M.2
Eichhorst, B.3
-
15
-
-
0036683449
-
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
-
Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
-
(2002)
Blood
, vol.100
, pp. 768-773
-
-
Lundin, J.1
Kimby, E.2
Bjorkholm, M.3
-
16
-
-
36448986964
-
Alemtuzumab (CAMPATH, MABCAMPATH) has superior progression-free survival vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL)
-
Abstract 301
-
Hillmen P, Skotnicki A, Robak T, et al. Alemtuzumab (CAMPATH, MABCAMPATH) has superior progression-free survival vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). Blood. 2006;108:93a. Abstract 301.
-
(2006)
Blood
, vol.108
-
-
Hillmen, P.1
Skotnicki, A.2
Robak, T.3
-
17
-
-
0030897222
-
Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia
-
Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol. 1997;15:1567-1574.
-
(1997)
J Clin Oncol
, vol.15
, pp. 1567-1574
-
-
Osterborg, A.1
Dyer, M.J.2
Bunjes, D.3
-
18
-
-
11144357657
-
Alemtuzimab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
-
Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzimab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.
-
(2004)
Blood
, vol.103
, pp. 3278-3281
-
-
Lozanski, G.1
Heerema, N.A.2
Flinn, I.W.3
|